Formycon AG delivers a breakthrough first‑quarter 2026 performance
The German biopharmaceutical company, listed on Xetra under the ticker FYB, announced that its first‑quarter 2026 results surpassed expectations, setting a new benchmark for growth within the biosimilars segment.
Revenue triple‑folding and EBITDA margin improvement
Formycon’s consolidated sales rose from €5.3 million in the same quarter of 2025 to €13.1 million in Q1 2026, representing a three‑fold increase. The company attributes the surge to a combination of milestone payments linked to the commercialization of its flagship product FYB203 and incremental sales from its contract‑service arm. While the operating loss widened from €8.6 million to €9.7 million, the EBITDA loss narrowed markedly, reflecting improved gross‑margin economics and a tighter cost base.
Strengthened biosimilar portfolio
The launch of FYB203 in the European Union has proven to be a pivotal driver. In the first quarter, the product generated €6.4 million in sales, up 138 % YoY, and secured a strategic partnership with a leading German pharmacy chain. The company’s biosimilar pipeline, which focuses on molecules whose patent protection is expiring, is now positioned to capture a growing share of the therapeutic market for biologics.
Cash flow and capital allocation
Despite the robust revenue growth, Formycon continues to manage its cash flow carefully. The company reiterated its guidance for the full fiscal year, forecasting total revenue to exceed €70 million and an EBITDA loss that will contract by roughly 30 % as the scale of operations expands. Management highlighted plans to invest in R&D, particularly in next‑generation biosimilars targeting oncology and autoimmune indications, while maintaining a disciplined approach to capital expenditure.
Market reaction and investor sentiment
Following the announcement, the stock traded at €22.60 on 28 May 2026, a modest 2.7 % rise from the prior close. Analysts noted that the company’s market cap of €384 million now reflects a price‑to‑earnings ratio of –5.94, underscoring the need for investors to consider the long‑term value created by the expanding portfolio. The 52‑week high of €31.30 and low of €15.80 illustrate the volatility inherent in the biopharmaceutical sector, yet the recent results provide a compelling case for a bullish outlook.
Outlook
Formycon’s management remains optimistic about the trajectory of its biosimilar platform. The company is preparing for the launch of two additional biosimilars in the coming year, aiming to capture a larger share of the growing biologics market in Europe. Continued focus on cost efficiencies, coupled with strategic partnerships, positions Formycon to sustain its rapid revenue growth while working toward profitability.
